CryoLife Reports Record Quarterly Revenues of $28...(e $3.9 million for each of the second qu...),Health

Other medical device revenues for the second quarter of 2009 were $1.5 million compared to $308,000 for the second quarter of 2008. Other medical device revenues for the first six months of 2009 were $2.7 million compared to $401,000 for the first six months of 2008. Included in this revenue category for the second quarter and the first six months of 2009 were $1.5 million and $2.6 million, respectively, in sales of HemoStase((TM)).

Total tissue processing and product gross margins were 63 percent and 66 percent for the second quarters of 2009 and 2008, respectively. Total tissue processing and product gross margins were 64 percent and 65 percent for the first six months of 2009 and 2008, respectively.

Tissue processing gross margins were 43 percent and 46 percent for the second quarters of 2009 and 2008, respectively. Tissue processing gross margins were 44 percent and 46 percent for the first six months of 2009 and 2008, respectively.

General, administrative, and marketing expenses for the second quarter of 2009 were $12.3 million compared to $12.4 million for the second quarter of 2008. General, administrative, and marketing expenses for the first six months of 2009 were $25.1 million compared to $24.4 million for the first six months of 2008. These expenses included personnel costs, advertising, physician education and training, and promotional materials to support the Company's efforts to increase its tissue processing service and product offerings, and current revenue growth.

General, administrative, and marketing expenses for the second quarters of 2009 and 2008 included benefits of $495,000 and $610,000, respectively, related to the adjustment of reserves for product
'/>"/>